EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)

Tomohiro Kadota, Rika Fujii, Shohei Koyama, Daisuke Kotani, Yusuke Yoda, Miki Fukutani, Mitsuko Suzuki, Masashi Wakabayashi, Takashi Ikeno, Hironori Sunakawa, Yoshiaki Nakamura, Akihito Kawazoe und 5 weitere

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01623-9 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Gastric Cancer, 2025. Verfasst von Tomohiro Kadota und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nivolumab, Immunotherapy, Phototherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Rakuten Medical, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Photoimmunotherapy with ASP-1929 (cetuximab conjugated to IRDye 700DX) and 690-nm red light has shown promising results, with a 43% objective response rate (ORR) in a phase IIa trial for recurrent head and neck squamous cell carcinoma. This study aimed to evaluate the safety and efficacy of combining photoimmunotherapy with nivolumab for advanced gastric cancer. METHODS: This phase Ib open-label, single-center trial investigated the combination of photoimmunotherapy with ASP-1929 and nivolumab in patients with unresectable EGFR-positive gastric adenocarcinoma after standard chemotherapy. The dose-escalation part aimed to determine the recommended dose of laser illumination energy under endoscopy, and the expansion part assessed the safety and efficacy at the determined dose. The primary endpoint was dose-limiting toxicity (DLT), and treatment response and adverse events were evaluated. RESULTS: Between October 2019 and April 2022, 21 patients were enrolled. All patients had previously received at least two lines of chemotherapy, with six being refractory to anti-PD-1 therapy. No DLT was observed, and the recommended dose was 100 J/cm2. Two patients achieved a partial response, and ORR was 9.5%. CONCLUSION: This study demonstrated that combining endoscopic photoimmunotherapy with nivolumab is safe and feasible for advanced gastric cancer. TRIAL REGISTRY: The trial is registered in the Japanese Registry of Clinical Trials (identifier: jRCT2080224884, https://jrct.niph.go.jp/en-latest-detail/jRCT2080224884 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNivolumabImmunotherapyPhototherapyCetuximabAdenocarcinomaHumansMaleFemaleAgedMiddle AgedAdult

Stichwörter der Autor:innen

Epidermal growth factor receptorNivolumabStomach neoplasms

Substanzen

NivolumabCetuximab

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
  • Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kshitara@east.ncc.go.jp.

ORCID-Profile: Kohei Shitara

Förderung

  • Rakuten Medical, Inc

Zitieren

APA

Kadota, T., Fujii, R., Koyama, S., Kotani, D., Yoda, Y., Fukutani, M., Suzuki, M., Wakabayashi, M., Ikeno, T., Sunakawa, H., Nakamura, Y., Kawazoe, A., Irie, T., Fuse, N., Sato, A., Yano, T., & Shitara, K. (2025). A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901). Gastric Cancer. https://doi.org/10.1007/s10120-025-01623-9

Vancouver

Kadota T, Fujii R, Koyama S, Kotani D, Yoda Y, Fukutani M, et al. A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901). Gastric Cancer. 2025. doi:10.1007/s10120-025-01623-9

BibTeX
@article{Kadota2025,
  author = {Kadota, Tomohiro and Fujii, Rika and Koyama, Shohei and Kotani, Daisuke and Yoda, Yusuke and Fukutani, Miki and Suzuki, Mitsuko and Wakabayashi, Masashi and Ikeno, Takashi and Sunakawa, Hironori and Nakamura, Yoshiaki and Kawazoe, Akihito and Irie, Takuma and Fuse, Nozomu and Sato, Akihiro and Yano, Tomonori and Shitara, Kohei},
  title = {A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01623-9}
}
Kostenlos starten →